DrugPatentWatch Database Preview

Details for Patent: 9,144,561

Which drugs does patent 9,144,561 protect, and when does it expire?

Patent 9,144,561 protects IZBA and is included in one NDA.

This patent has thirty patent family members in twenty countries.

Summary for Patent: 9,144,561

Title:	Pharmaceutical compositions having desirable bioavailability
Abstract:	The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s):	Kabra; Bhagwati P. (Euless, TX)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	14/267,668
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,144,561
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,144,561

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,144,561

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,178,582	Pharmaceutical compositions having desirable bioavailability	➤ Sign Up
8,754,123	Pharmaceutical compositions having desirable bioavailability	➤ Sign Up
8,722,735	Pharmaceutical compositions having desirable bioavailability	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 9,144,561

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Taiwan	I544927	➤ Sign Up
Taiwan	200940068	➤ Sign Up
Slovenia	2265251	➤ Sign Up
Russian Federation	2503453	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,144,561

For more information try a trial or see the plans and pricing